Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinoma

Cancer Science

Volumn 99, Issue 6, 2008, Pages 1188-1194

  Ramankulov, Azizbek ^a,b   Lein, Michael ^a,c   Johannsen, Manfred ^a   Schrader, Mark ^a   Miller, Kurt ^a   Jung, Klaus ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Republic Center of Urology   (Czech Republic)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MATRILYSIN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 43549090222     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00802.x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Russo P. Localized renal cell carcinoma. Curr Treat Options Oncol 2001; 2: 447-55.
3. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 385-90.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.
5. Jung K, Lein M, Ringsdorf M et.al. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 2006; 176: 1326-31.
6. Kashyap MK, Kumar A, Emelianenko N et al. Biochemical and molecular markers in renal cell carcinoma: An update and future prospects. Biomarkers 2005; 10: 258-94.
7. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003; 3: 31.
8. Jones J, Otu H, Spentzos D et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730-9.
9. Sumi T, Nakatani T, Yoshida H et al. Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma. Oncol Rep 2003; 10: 567-70.
10. Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: Prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 2006; 12: 6998-7003.
11. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
12. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-17.
13. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005; 87: 307-14.
14. Patten LC, Berger DH. Role of proteases in pancreatic carcinoma. World J Surg 2005; 29: 258-63.
15. Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol 2007; 25: 407-11.
16. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-7.
17. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-66.
18. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95.kDa and 72.kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277: 277-9.
19. Sires UI, Griffin GL, Broekelmann TJ et al. Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem 1993; 268: 2069-74.
20. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999; 45: 252-8.
21. Jiang WG, Davies G, Martin TA et al. Targeting matrilysin and its impact on tumor growth in vivo: The potential implications in breast cancer therapy. Clin Cancer Res 2005; 11: 6012-9.
22. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004; 10: 2832-45.
23. Luo HZ, Zhou ZG, Yang L et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol 2005; 35: 739-44.
24. Maurel J, Nadal C, Garcia-Albeniz X et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007; 121: 1066-71.
25. Yamamoto H, Iku S, Adachi Y et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003; 199: 176-84.
26. Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000; 6: 1169-74.
27. Zucker S, Doshi K, Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: Potential clinical applications. Adv Clin Chem 2004; 38: 37-85.
28. Kuhlmann KF, van Till JW, Boermeester MA et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 886-91.
29. Sarkissian G, Fergelot P, Lamy P-J et al. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 2008; published online January 17:dOi: 10.1373/ clinchem.2007.090837.
30. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss, 1997.
31. Solberg HE. Approved recommendations (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determinations of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-56.
32. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-7.
33. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J 1990; 4: 1577-90.
34. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
35. Crabbe T, Smith B, O'Connell J, Docherty A. Human progelatinase A can be activated by matrilysin. FEBS Lett 1994; 345: 14-16.
36. von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem J 1998; 331: 965-72.
37. Nakamura M, Miyamoto S, Maeda H et al. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005; 333: 1011-6.
38. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28.261-7.
39. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-81.
40. Jung K, Klotzek S, Stephan C, Mannello F, Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and, 9. Clin Chem 2008. accepted: January 7, 2008.
41. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-4.
42. Kyzas PA, axa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: Association with reported prognostic effect. J Natl Cancer Inst 2007; 99: 236-43.
43. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005; 97: 1043-55.
44. Kyzas PA, axa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559-79.